Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study.

ABSTRACT:

Background

Individuals with a family history of colorectal cancer (CRC) are at a high risk of developing CRC. Preclinical studies suggest that the anti-malaria drug proguanil and atovaquone might play a role in preventing CRC, but population-based evidence is still lacking.

Methods

By accessing a couple of nationwide Swedish registers, we performed a cohort study to explore whether using proguanil and atovaquone might associate with a lower risk of CRC by adopting a new-user study design. Adults who have 1 or more first-degree relatives (parents or siblings) diagnosed with CRC were identified and linked with the Prescribed Drug Register to evaluate their administration history of proguanil and atovaquone. Survival analysis of the time to CRC diagnosis with Cox proportional h

SUBMITTER: Zhang N 

PROVIDER: S-EPMC9650910 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature